.Nature Medicine, Released online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized stage 3b/4 DESTINY-Breast12 study, trastuzumab deruxtecan (T-DXd) treatment of individuals with HER2+ sophisticated breast cancer and active or even secure brain metastases revealed regular intracranial task as well as wide spread efficacy of T-DXd.